Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Why Biogen Stock Was a Winner on Wednesday

🧬 Biogen's stock surged 6% after releasing Q1 2026 earnings that beat analyst revenue estimates.

💰 Total revenue reached $2.48 billion, a 2% year-over-year increase versus the consensus forecast of $2.25 billion.

🚀 Attributable non-GAAP net income grew 19% to approximately $529 million, or $3.57 per share against estimates of $2.95.

🧠 Sales of Leqembi for Alzheimer's treatment jumped 74% year-over-year to $168 million, driving growth product revenue.

❤️ Skyclarys also posted double-digit growth as the only FDA-approved drug for Friedreich's ataxia.

⚠️ Biogen lowered its full-year adjusted net income guidance by approximately $1 per share due to in-process research and development charges.

📉 Revenue is now projected to decline at a mid-single-digit percentage rate compared to 2025 levels.

🤝 The financial outlook excludes the pending acquisition of Apellis Pharmaceuticals, which carries a $5.6 billion valuation.

🔄 Biogen continues its strategic transformation from multiple sclerosis treatments to therapies in high-potential areas like Alzheimer's.

🧑‍💼 Analyst Eric Volkman expressed confidence in the strategy and stated he would be a buyer of Biogen stock.

🏆 The Motley Fool recommends holding Biogen but notes it was not included in their top 10 current buy list.

📈 Historical examples cited include Netflix (Dec 2004) and Nvidia (April 2005) appearing in similar future-looking investment lists.

❗ Stock Advisor boasts a total average return of 985% compared to the S&P 500's 200%.

⏳ The article mentions returns data as of April 29, 2026.

📜 The Motley Fool recommends Biogen and maintains its standard disclosure policy regarding analyst positions.

Bullish Signals
  • Biogen's shares gained 6% by the end of trading Wednesday as investors piled into the stock following its earnings report.
  • The company reported Q1 2026 total revenue of $2.48 billion, a 2% year-over-year increase that beat analyst consensus estimates of $2.25 billion.
  • Biogen's non-GAAP attributable net income rose dramatically by 19% to slightly over $529 million, or $3.57 per share.
  • The stock significantly topped Wall Street expectations as analysts were only modeling $2.95 per share for earnings per share.
  • Revenue growth was driven by 'growth products' where sales of Leqembi, the Alzheimer's drug, zoomed 74% higher to $168 million.
  • Skyclarys also showed double-digit growth as the only FDA-approved medication for Friedreich's ataxia.
  • Biogen is acquiring Apellis Pharmaceuticals in a deal valued at $5.6 billion, which will not be included in current revenue projections but adds value.
  • The acquisition is expected to close in the near future, further supporting Biogen's transformation into high-potential therapies.
Risk Factors
  • Despite beating quarterly earnings estimates, Biogen lowered its full-year adjusted net income guidance to $14.25-$15.25 per share, a decrease of $1 on either end from the previous forecast.
  • The company expects revenue to continue declining at a mid-single-digit percentage rate compared to 2025 levels.
  • Biogen faces significant cash outflow risks as it proceeds with the acquisition of Apellis Pharmaceuticals for a total deal value of $5.6 billion, which is not included in current revenue projections.
  • The guidance cuts are driven by anticipated charges from acquired in-process research and development, indicating upcoming accounting headwinds.
Full Analysis
Prominent biotech firm Biogen (NASDAQ: BIIB) saw its stock price rise 6% on Wednesday following the release of strong first-quarter earnings that exceeded analyst expectations. Despite a notable cut to full-year profitability guidance, investors reacted positively to the results, driving shares up by the end of trading. Biogen reported total revenue for the first quarter of 2026 at $2.48 billion, representing a 2% year-over-year increase and topping the consensus forecast of $2.25 billion. Profitability showed significant improvement compared to earnings per share models, with attributable non-GAAP net income rising 19% to approximately $529 million, or $3.57 per share, against an analyst expectation of $2.95 per share. This growth was primarily driven by Biogen's portfolio of "growth products," where sales of Leqembi, a treatment for early Alzheimer's disease, surged 74% to reach $168 million in the quarter. Skyclarys also contributed to revenue growth as another approved medication for Friedreich's ataxia. However, Biogen lowered its full-year adjusted net income guidance to a range of $14.25 to $15.25 per share, down from a previous forecast of $15.25 to $16.25 per share. The revision is attributed to anticipated charges related to acquired in-process research and development. Additionally, the company expects revenue to continue declining at a mid-single-digit rate compared to 2025. These financial projections do not factor in the upcoming acquisition of Apellis Pharmaceuticals, which is valued at $5.6 billion and expected to close soon as part of Biogen's strategy to transform from a multiple sclerosis specialist to a provider of other high-potential therapies. The article concludes with perspectives from The Motley Fool analyst team, which expresses confidence in Biogen's long-term transformation strategy and recommends the stock for purchase. In contrast, the Stock Advisor service did not include Biogen in its list of top 10 stocks, highlighting past successes such as early recommendations for Netflix and Nvidia while promoting their broader investment services.